基于复制缺陷型猿腺病毒载体ChAdOx1的疫苗:用于风险/获益评估的标准化模板及关键考量
ChAdOx1是一种基于猿腺病毒Y25型的复制缺陷型腺病毒载体,2012年以来已在多项临床试验中评估。本文综述其载体特征、生产工艺、热稳定性及安全性数据,汇总Ⅰ-Ⅲ期临床试验与新冠疫苗上市后监测结果,总体耐受良好,极罕见报告TTS、CLS、ITP和GBS,多数情况下获益大于严重不良事件风险。
要点
- ChAdOx1载体基于猿腺病毒Y25型,E1基因缺失使其复制缺陷,E3和E4基因改造提高插入容量并优化生产。
- 该载体疫苗可在E1互补细胞系中规模化生产且热稳定,首款新冠疫苗于2020年12月30日在英国获紧急使用授权。
- 大规模接种后极罕见报告TTS、CLS、ITP和GBS,多数情况下获益大于严重不良事件风险。
核心结论
- ChAdOx1载体疫苗总体耐受良好,新冠疫苗接种在多数情况下获益大于严重不良事件风险,尤其在可能时采取风险缓解措施。
- ChAdOx1载体疫苗可诱导强而持久的体液和细胞免疫应答。
研究设计与样本
- Brighton Collaboration疫苗技术获益-风险评估(BRAVATO) formed to evaluate the safety and other key features of new platform technology vaccines,本文综述ChAdOx1载体疫苗的关键特征。
- 安全性数据汇总自牛津大学开展的表达不同抗原(流感、结核、疟疾、脑膜炎B、前列腺癌、MERS-CoV、基孔肯雅、寨卡和SARS-CoV-2)的ChAdOx1载体疫苗Ⅰ-Ⅲ期临床试验,以及COVID-19牛津-阿斯利康疫苗的上市后监测数据。
主要发现
- 选择猿腺病毒Y25型是为了规避对常见人腺病毒血清型的预存免疫,预存免疫可能损害腺病毒载体疫苗诱导的免疫应答。
- E1基因缺失使ChAdOx1载体复制无能,E3和E4基因的进一步基因工程改造可提高插入能力并优化疫苗生产工艺。
- ChAdOx1载体疫苗可在E1互补细胞系中规模化生产且热稳定。
- 首个获批人用的ChAdOx1载体疫苗针对SARS-CoV-2,于2020年12月30日在英国获紧急使用授权,现已在超过180个国家获批。
- 大规模接种COVID-19牛津-阿斯利康疫苗后极罕见报告血栓形成伴血小板减少综合征(TTS)、毛细血管渗漏综合征(CLS)、免疫性血小板减少症(ITP)和吉兰-巴雷综合征(GBS)。
临床怎么用
- 作者指出,多数情况下新冠疫苗接种的获益大于严重不良事件风险,尤其在可能时采取风险缓解措施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform technology vaccines. This manuscript reviews key features of the ChAdOx1-vectored vaccines. The simian adenovirus Y25 was chosen as a strategy to circumvent pre-existing immunity to common human adenovirus serotypes which could impair immune responses induced by adenoviral vectored vaccines. Deletion of the E1 gene renders the ChAdOx1 vector replication incompetent and further genetic engineering of the E3 and E4 genes allows for increased insertional capability and optimizes vaccine manufacturing processes. ChAdOx1 vectored vaccines can be manufactured in E1 complementing cell lines at scale and are thermostable. The first ChAdOx1 vectored vaccines approved for human use, against SARS-CoV-2, received emergency use authorization in the UK on 30th December 2020, and is now approved in more than 180 countries. Safety data were compiled from phase I-III clinical trials of ChAdOx1 vectored vaccines expressing different antigens (influenza, tuberculosis, malaria, meningococcal B, prostate cancer, MERS-CoV, Chikungunya, Zika and SARS-CoV-2), conducted by the University of Oxford, as well as post marketing surveillance data for the COVID-19 Oxford-AstraZeneca vaccine. Overall, ChAdOx1 vectored vaccines have been well tolerated. Very rarely, thrombosis with thrombocytopenia syndrome (TTS), capillary leak syndrome (CLS), immune thrombocytopenia (ITP), and Guillain-Barre syndrome (GBS) have been reported following mass administration of the COVID-19 Oxford-AstraZeneca vaccine. The benefits of this COVID-19 vaccination have outweighed the risks of serious adverse events in most settings, especially with mitigation of risks when possible. Extensive immunogenicity clinical evaluation of ChAdOx1 vectored vaccines reveal strong, durable humoral and cellular immune responses to date; studies to refine the COVID-19 protection (e.g., via homologous/heterologous booster, fractional dose) are also underway. New prophylactic and therapeutic vaccines based on the ChAdOx1 vector are currently undergoing pre-clinical and clinical assessment, including vaccines against viral hemorrhagic fevers, Nipah virus, HIV, Hepatitis B, amongst others.
引用
- Folegatti PM, Jenkin D, Morris S, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2022. PMID: 35715352. doi:10.1016/j.vaccine.2022.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。